Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
75 hedge funds and large institutions have $36.5M invested in Adverum Biotechnologies in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 15 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
0.4% less ownership
Funds ownership: 3.62% → 3.22% (-0.4%)
10% less funds holding
Funds holding: 83 → 75 (-8)
17% less capital invested
Capital invested by funds: $43.8M → $36.5M (-$7.27M)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.99M |
| 2 |
CC
Casdin Capital
New York
|
+$1.19M |
| 3 |
AIC
AWM Investment Company
New York
|
+$569K |
| 4 |
Renaissance Technologies
New York
|
+$490K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$411K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.66M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$511K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$485K |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$419K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$377K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GPCM
76
Granite Point Capital Management
Boston,
Massachusetts
| – | -$377K | -13,000 | Closed |
|
|
AFM
77
Anson Funds Management
Dallas,
Texas
| – | -$373K | -12,854 | Closed |
|
|
DMK
78
David M. Knott
| – | -$191K | -6,600 | Closed |
|
79
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$159K | -5,488 | Closed |
|
|
TCM
80
Teza Capital Management
Chicago,
Illinois
| – | -$148K | -5,106 | Closed |
|
|
BIM
81
Bogle Investment Management
Newton Lower Falls,
Massachusetts
| – | -$108K | -3,756 | Closed |
|
82
Goldman Sachs
New York
| – | -$108K | -3,725 | Closed |
|
|
TI
83
Turner Investments
Berwyn,
Pennsylvania
| – | -$73K | -2,500 | Closed |
|
|
VKH
84
Virtu KCG Holdings
New York
| – | -$58K | -1,995 | Closed |
|
|
IAM
85
Integre Asset Management
New York
| – | -$45K | -1,548 | Closed |
|
|
CS
86
Credit Suisse
Zurich,
Switzerland
| – | -$35K | -1,198 | Closed |
|
|
CG
87
Cutler Group
San Francisco,
California
| – | -$4K | -170 | Closed |
|
88
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -109 | Closed |
|
89
Simplex Trading
Chicago,
Illinois
| – | -$1K | -61 | Closed |
|
ADVM Hedge Fund Activity: Q1 2017 in Review
75 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2017, worth a combined $36.5M — down 17% from $43.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ADVM and 12 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $3.99M. The largest seller was Fidelity Investments, cutting an estimated $2.66M.
- 75 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2017, down from 83 in Q4 2016.
- Funds reported $36.5M of Adverum Biotechnologies stock for Q1 2017, down 17% quarter-over-quarter.
- 12 funds opened new Adverum Biotechnologies positions in Q1 2017 and 15 closed out, a net change of -3 holders.
- The largest Adverum Biotechnologies buyer in Q1 2017 was BlackRock, an estimated $3.99M added.
- The largest Adverum Biotechnologies seller in Q1 2017 was Fidelity Investments, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2017.